The Otsuka and Noven successes from 2018 portend a new era of drug development, one in which treatment efficacy is established in the context of the patient's overall life and behavior. It is time for measurement science to follow and embrace the fact that how we measure outcomes will evolve from applying one solution to finding an empirical basis for a highly customized application of all of them, enabled by technology. Personalized medicine needs a more personalized approach to measurement.
Benchmark your study enrollment versus competitors
Get Benchmark DataOther content in this Stream
Despite advances in science, medicine and tech, 90% of clinical trials struggle to meet enrollment. We propose flipping the funnel to address site resourcing issue and convert recruits into enrollees.
Learn what high-performing research sites have in common, and what makes sponsors return to them again and again.
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
52:22Learn how to engage sites more effectively with the appropriate recruitment resources, use dedicated staff to manage recruitment efforts, and eliminate bottlenecks and expedite recruitment timelines.
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
Often, the only way for potential research subjects to learn about a clinical trial is through recruitment materials. But what materials must you submit to the IRB for review?
Nearly half of all clinical trials still use paper as the primary - or even sole - source of records while barely a quarter of trials use eCOA or ePRO
CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials
Our client, a Top 10 pharmaceutical company, needed to boost enrollment for their phase ll pediatric sickle cell anemia study.
A leading pharma company needed assistance to rescue their enrolling ophthalmology study. The sponsor was attempting to complete enrollment for a normative, glaucoma and retinal disease study.
Our customer needed support for a global, multi-protocol program which was behind with enrollment.